CD86 and acute myeloid leukemia: Particularly, DNMT and HDAC inhibitors may result to an upregulation of TAAs and of co-stimulatory molecules such as CD40, CD80, CD86 and MHC classes I and II, on tumor cells, in particular in Acute Myeloid Leukemia (AML) cell lines (Maeda et al., 2000; Magner et al., 2000).